Investor Relations

Eton Pharmaceuticals, Inc. is a commercial company focused on developing, acquiring, and commercializing high-potential therapies for the treatment of patients with rare diseases. We have a diversified pipeline of product candidates across multiple therapeutic areas, and a team with significant expertise in bringing products from clinical trials to patients with exceptional speed.

Volume :

Minimum 15 minutes delayed. Source: LSEG

News Releases
March 19, 2026
Q4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024 Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS of $0.19, and Adjusted EBITDA of $6.2 million Launched DESMODA™, the first and only FDA-approved
March 3, 2026
DEER PARK, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2025
March 2, 2026
HEMANGEOL® is the only FDA-approved treatment for infantile hemangioma HEMANGEOL will be commercialized by Eton beginning May 1 st HEMANGEOL will be distributed through the company’s Eton Cares™ patient support program, which includes a $0 co-pay initiative, to broaden patient access.